Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference
Retrieved on:
Tuesday, January 19, 2021
The data were presented in poster format online for the 2021 Winter Clinical Dermatology Conference.
Key Points:
- The data were presented in poster format online for the 2021 Winter Clinical Dermatology Conference.
- VP-102, our lead candidate, continues to demonstrate positive results as we advance development of the program in molluscum, external genital warts and common warts, three of the largest unmet needs in medical dermatology.
- Data were also presented from Verricas Phase 2 CARE-1 clinical study of VP-102 in external genital warts (EGW).
- Verricas late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and external genital warts, three of the largest unmet needs in medical dermatology.